Zelalem Eshete

Array ( [id] => 8239790 [patent_doc_number] => 20120148514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-14 [patent_title] => 'N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/296361 [patent_app_country] => US [patent_app_date] => 2011-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13665 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13296361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8435592 [patent_doc_number] => 08283362 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-10-09 [patent_title] => 'Beta-2-adrenoreceptor agonists' [patent_app_type] => utility [patent_app_number] => 13/295426 [patent_app_country] => US [patent_app_date] => 2011-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18999 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13295426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8265893 [patent_doc_number] => 20120165319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-28 [patent_title] => 'INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME' [patent_app_type] => utility [patent_app_number] => 13/293592 [patent_app_country] => US [patent_app_date] => 2011-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 134058 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13293592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9896195 [patent_doc_number] => 20150051394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES' [patent_app_type] => utility [patent_app_number] => 14/349648 [patent_app_country] => US [patent_app_date] => 2011-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13342 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14349648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10050761 [patent_doc_number] => 09090629 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-28 [patent_title] => 'Cytotoxic agents comprising new ansamitocin derivatives' [patent_app_type] => utility [patent_app_number] => 13/883344 [patent_app_country] => US [patent_app_date] => 2011-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 41 [patent_no_of_words] => 27838 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13883344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9245393 [patent_doc_number] => 08609674 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-17 [patent_title] => 'Potassium channel modulators' [patent_app_type] => utility [patent_app_number] => 13/287647 [patent_app_country] => US [patent_app_date] => 2011-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26572 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13287647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7778479 [patent_doc_number] => 20120040971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-16 [patent_title] => 'BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS' [patent_app_type] => utility [patent_app_number] => 13/283231 [patent_app_country] => US [patent_app_date] => 2011-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21026 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0040/20120040971.pdf [firstpage_image] =>[orig_patent_app_number] => 13283231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8964133 [patent_doc_number] => 20130203735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-08 [patent_title] => 'CAPROLACTAM MGLUR5 RECEPTOR MODULATORS' [patent_app_type] => utility [patent_app_number] => 13/880441 [patent_app_country] => US [patent_app_date] => 2011-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17668 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13880441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7768070 [patent_doc_number] => 20120035202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-09 [patent_title] => 'RIFAXIMIN COMPOSITIONS AND METHOD OF USE' [patent_app_type] => utility [patent_app_number] => 13/275257 [patent_app_country] => US [patent_app_date] => 2011-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4898 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0035/20120035202.pdf [firstpage_image] =>[orig_patent_app_number] => 13275257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8359631 [patent_doc_number] => 20120214794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-23 [patent_title] => 'HETEROARYLS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/272413 [patent_app_country] => US [patent_app_date] => 2011-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83086 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13272413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8964137 [patent_doc_number] => 20130203739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-08 [patent_title] => 'CYCLIC AMIDE DERIVATIVE' [patent_app_type] => utility [patent_app_number] => 13/877626 [patent_app_country] => US [patent_app_date] => 2011-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110275 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13877626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9009423 [patent_doc_number] => 08524721 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-03 [patent_title] => 'Platelet ADP receptor inhibitors' [patent_app_type] => utility [patent_app_number] => 13/270193 [patent_app_country] => US [patent_app_date] => 2011-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22538 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13270193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8591966 [patent_doc_number] => 08349843 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-01-08 [patent_title] => 'Carboxylic acid derivatives, their preparation and use' [patent_app_type] => utility [patent_app_number] => 13/267178 [patent_app_country] => US [patent_app_date] => 2011-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14274 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13267178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8054071 [patent_doc_number] => 20120076755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-29 [patent_title] => 'Hepatitis C Virus Inhibitors' [patent_app_type] => utility [patent_app_number] => 13/252818 [patent_app_country] => US [patent_app_date] => 2011-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33084 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0076/20120076755.pdf [firstpage_image] =>[orig_patent_app_number] => 13252818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7756717 [patent_doc_number] => 20120028908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-02 [patent_title] => 'Methods of Manufacturing Crystalline Forms of Rapamycin Analogs' [patent_app_type] => utility [patent_app_number] => 13/251207 [patent_app_country] => US [patent_app_date] => 2011-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 24117 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0028/20120028908.pdf [firstpage_image] =>[orig_patent_app_number] => 13251207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9350469 [patent_doc_number] => 08669360 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-11 [patent_title] => 'Methods of converting amorphous drug substance into crystalline form' [patent_app_type] => utility [patent_app_number] => 13/242433 [patent_app_country] => US [patent_app_date] => 2011-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4746 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13242433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8977641 [patent_doc_number] => 20130211071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'METHOD FOR MAKING ALPHA-AMINO-EPSILON-CAPROLACTAM USING MIXED SUPER CRITICAL FLUIDS' [patent_app_type] => utility [patent_app_number] => 13/825799 [patent_app_country] => US [patent_app_date] => 2011-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1073 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13825799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8141365 [patent_doc_number] => 20120095211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-19 [patent_title] => 'SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION' [patent_app_type] => utility [patent_app_number] => 13/237843 [patent_app_country] => US [patent_app_date] => 2011-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68871 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 35 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0095/20120095211.pdf [firstpage_image] =>[orig_patent_app_number] => 13237843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9060130 [patent_doc_number] => 08546566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-01 [patent_title] => 'Process for manufacturing dihydropteridinones and intermediates thereof' [patent_app_type] => utility [patent_app_number] => 13/233066 [patent_app_country] => US [patent_app_date] => 2011-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5010 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13233066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8054293 [patent_doc_number] => 20120076857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-29 [patent_title] => 'FORMS OF RIFAXIMIN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/226053 [patent_app_country] => US [patent_app_date] => 2011-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 21937 [patent_no_of_claims] => 139 [patent_no_of_ind_claims] => 27 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0076/20120076857.pdf [firstpage_image] =>[orig_patent_app_number] => 13226053 [rel_patent_id] =>[rel_patent_doc_number] =>)